Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569127 · ClinicalTrials.gov registry record · Phase 3
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
A Phase 3 study of Neuroendocrine Tumor and Neuroendocrine Neoplasm, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 3
- Development phase
- 427
- Enrollment target
- 20
- Study locations
NCT00569127 is a Phase 3 study of Neuroendocrine Tumor and Neuroendocrine Neoplasm that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 427 participants, above the 73-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (485% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00569127, a Phase 3 study of Neuroendocrine Tumor and Neuroendocrine Neoplasm, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 427 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic) or spread from where it started to nearby tissue or lymph nodes (locally advanced). Octreotide acetate and recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving octreotide acetate together with recombinant interferon alfa-2b is more effective than giving octreotide acetate together with bevacizumab in treating patients with neuroendocrine tumor.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
- DRUG Octreotide Acetate
- BIOLOGICAL Recombinant Interferon Alfa-2b
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Arroyo Grande Community - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Alta Bates Summit Medical Center-Herrick Campus - Berkeley
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mills-Peninsula Medical Center - Burlingame
- Kaiser Permanente-Fontana - Fontana
- Marin General Hospital - Greenbrae
- Kaiser Permanente South Bay - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Los Angeles General Medical Center - Los Angeles
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group - Rogers - Rogers
Alabama
- Providence Hospital - Mobile
Alaska
- Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2007-12-01 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569127
The ClinicalTrials.gov registry entry for NCT00569127 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (485% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neuroendocrine Tumor appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00569127 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00569127 about?
NCT00569127 is a clinical study titled "Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor". This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic) or spread from whe...
What is the current status of trial NCT00569127?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 427 participants. The study started on 2007-12-01. Estimated completion is 2027-01-31.
What conditions does trial NCT00569127 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor, Neuroendocrine Neoplasm, Neuroendocrine Tumor G2, Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1.
What interventions are being tested in trial NCT00569127?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Octreotide Acetate (DRUG), Recombinant Interferon Alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00569127?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00569127 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
RECRUITING · Early Phase 1
-
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
RECRUITING · NA
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
COMPLETED · Phase 2
-
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
COMPLETED · Phase 2
-
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.